Federici M, Porzio O, Zucaro L, Giovannone B, Borboni P, Marini M A, Lauro D, Sesti G
Department of Internal Medicine, University of Rome-Tor Vergata, Italy.
Mol Cell Endocrinol. 1997 Nov 30;135(1):41-7. doi: 10.1016/s0303-7207(97)00185-8.
Insulin/IGF-I hybrid receptors composed of an insulin receptor (IR) alphabeta-hemireceptor and a type 1 IGF receptor (IGF-IR) alphabeta-hemireceptor are formed in tissues expressing both molecules. To date there is a limited information about the proportion of hybrids in tissues of normal or diabetic subjects. In this study, we determined the abundance of hybrids in fat from control and NIDDM subjects by using a microwell-based immunoassay. Microwells coated with MA-20 anti-IR or alpha-IGF-IR-PA anti-IGF-IR antibody were incubated with tissue extracts. Immunoadsorbed receptors were incubated with 125I-insulin or 125I-IGF-I in the presence or absence of unlabeled ligands, and hybrids were quantitated as the fraction of 125I-IGF-I binding immunoadsorbed with MA-20. Abundance of hybrids was increased in NIDDM patients as compared with controls (B/T = 1.29 +/- 0.18 and 0.52 +/- 0.06%; P < 0.008, respectively), and it was inversely correlated with both IR number (r = -0.65; P < 0.002), and in vivo insulin sensitivity measured by insulin tolerance test (r = -0.75; P < 0.005), whereas it was positively correlated with insulinemia (r = 0.63; P < 0.003). Insulin binding affinity was lower in NIDDM subjects than in controls (ED50 = 1.87 +/- 0.32 and 0.54 +/- 0.20 nmol/l; P < 0.009, respectively), and was correlated with the percentage of hybrids. Maximal IGF-I binding was significantly greater in NIDDM patients than controls and was positively correlated with the percentage of hybrids whereas IGF-I binding affinity did not differ between the two groups. Results show that expression of hybrids is increased in fat of NIDDM patients compared to control subjects and is correlated with in vivo insulin sensitivity thus raising the possibility that alterations in expression of hybrids which bind IGF-I with higher affinity than insulin may contribute, at least in part, to insulin resistance.
由胰岛素受体(IR)αβ半受体和1型胰岛素样生长因子受体(IGF-IR)αβ半受体组成的胰岛素/IGF-I杂合受体在同时表达这两种分子的组织中形成。迄今为止,关于正常或糖尿病患者组织中杂合体比例的信息有限。在本研究中,我们使用基于微孔板的免疫测定法测定了对照组和非胰岛素依赖型糖尿病(NIDDM)患者脂肪中杂合体的丰度。将包被有MA-20抗IR或α-IGF-IR-PA抗IGF-IR抗体的微孔板与组织提取物孵育。将免疫吸附的受体在有无未标记配体的情况下与125I-胰岛素或125I-IGF-I孵育,杂合体定量为与MA-20免疫吸附的125I-IGF-I结合部分。与对照组相比,NIDDM患者杂合体的丰度增加(B/T分别为1.29±0.18和0.52±0.06%;P<0.008),并且与IR数量(r=-0.65;P<0.002)以及通过胰岛素耐量试验测量的体内胰岛素敏感性(r=-0.75;P<0.005)呈负相关,而与胰岛素血症呈正相关(r=0.63;P<0.003)。NIDDM患者的胰岛素结合亲和力低于对照组(ED50分别为1.87±0.32和0.54±0.20 nmol/l;P<0.009),并且与杂合体的百分比相关。NIDDM患者的最大IGF-I结合显著高于对照组,并且与杂合体的百分比呈正相关,而两组之间的IGF-I结合亲和力没有差异。结果表明,与对照组相比,NIDDM患者脂肪中杂合体的表达增加,并且与体内胰岛素敏感性相关,因此增加了与胰岛素相比以更高亲和力结合IGF-I的杂合体表达改变可能至少部分导致胰岛素抵抗的可能性。